1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

 
• By Alaric DeArment

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

T-cells attacking cancer_1200x675
Merck and Eisai published data in NEJM from the KEYNOTE-775 study of Keytruda/Lenvima in endometrial carcinoma • Source: Shutterstock

Newly published data from a study combining Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab) and Eisai Co., Ltd.’s multiple tyrosine kinase inhibitor Lenvima (lenvatinib) in endometrial carcinoma adds to Keytruda’s growing repertoire of data in women’s cancers. With recent approvals in key settings of cervical cancer and triple-negative breast cancer (TNBC), Keytruda has taken a lead in cancers affecting women, even as other players played catch-up or stumbled.

Data from the Phase III KEYNOTE-775 study in patients with advanced endometrial carcinoma were published on 20 January in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?